B+
Bull case
30%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
MIRM
MirumBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+83.4
Score
AI commentary
News flow is clearly constructive into May 2026: positive VISTAS headlines on May 4 and a beat-and-raise style earnings update on May 6. Immediate reaction evidence is mixed in low-trust market summaries, but the verified tape shows MIRM closed at $102.93 on May 7, 2026 and traded at $107.16 on May 8, 2026, indicating the post-release setup remained positive. Analyst revision visibility was still limited in the checked sources, so this remains a cautious positive-monitoring view rather than a high-conviction post-earnings upgrade.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06catalystQ1 2026 update raised revenue guidance and reinforced commercial executionHigh impact
Mirum’s May 6, 2026 earnings update highlighted Q1 2026 net product sales of $159.9 million, a raise in 2026 net product sales guidance to $660 million-$680 million from the prior $630 million-$650 million range, and unrestricted cash, cash equivalents and investments of $420.6 million as of March 31, 2026; the same filing also notes the update was furnished on Form 8-K and provides at least 12 months of operating runway [#8-K-2026-05-06] [#10-Q-2026-05-06].
2026-09-26eventZilurgisertib Priority Review adds a new rare-disease launch option in 2026High impact
Mirum disclosed in its March 31, 2026 10-Q that it entered an April 2026 agreement with Incyte to obtain commercialization rights to zilurgisertib upon FDA approval, and that the NDA has been accepted with a September 26, 2026 PDUFA date, creating a discrete regulatory catalyst outside the existing cholestatic liver and HDV programs [#10-Q-2026-05-06].
2026-10-31catalystBrelovitug AZURE topline data can open a 2027 BLA pathHigh impact
Mirum said on March 5, 2026 that AZURE-1 enrollment and AZURE-4 screening were complete, with topline 24-week data expected in the second half of 2026 and the two studies intended to support a U.S. BLA submission; this is one of the company’s largest pipeline value drivers but remains binary and integration-sensitive.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology